249 related articles for article (PubMed ID: 29668342)
1. Sequencing the next generation of glioblastomas.
Jovčevska I
Crit Rev Clin Lab Sci; 2018 Jun; 55(4):264-282. PubMed ID: 29668342
[TBL] [Abstract][Full Text] [Related]
2. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma.
Ramkissoon SH; Bi WL; Schumacher SE; Ramkissoon LA; Haidar S; Knoff D; Dubuc A; Brown L; Burns M; Cryan JB; Abedalthagafi M; Kang YJ; Schultz N; Reardon DA; Lee EQ; Rinne ML; Norden AD; Nayak L; Ruland S; Doherty LM; LaFrankie DC; Horvath M; Aizer AA; Russo A; Arvold ND; Claus EB; Al-Mefty O; Johnson MD; Golby AJ; Dunn IF; Chiocca EA; Trippa L; Santagata S; Folkerth RD; Kantoff P; Rollins BJ; Lindeman NI; Wen PY; Ligon AH; Beroukhim R; Alexander BM; Ligon KL
Neuro Oncol; 2015 Oct; 17(10):1344-55. PubMed ID: 25754088
[TBL] [Abstract][Full Text] [Related]
3. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ
Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures.
Johnson A; Severson E; Gay L; Vergilio JA; Elvin J; Suh J; Daniel S; Covert M; Frampton GM; Hsu S; Lesser GJ; Stogner-Underwood K; Mott RT; Rush SZ; Stanke JJ; Dahiya S; Sun J; Reddy P; Chalmers ZR; Erlich R; Chudnovsky Y; Fabrizio D; Schrock AB; Ali S; Miller V; Stephens PJ; Ross J; Crawford JR; Ramkissoon SH
Oncologist; 2017 Dec; 22(12):1478-1490. PubMed ID: 28912153
[TBL] [Abstract][Full Text] [Related]
5. Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats.
Movassaghi M; Shabihkhani M; Hojat SA; Williams RR; Chung LK; Im K; Lucey GM; Wei B; Mareninov S; Wang MW; Ng DW; Tashjian RS; Magaki S; Perez-Rosendahl M; Yang I; Khanlou N; Vinters HV; Liau LM; Nghiemphu PL; Lai A; Cloughesy TF; Yong WH
Exp Mol Pathol; 2017 Aug; 103(1):87-93. PubMed ID: 28663030
[TBL] [Abstract][Full Text] [Related]
6. Detection of TERT Promoter Mutations Using Targeted Next-Generation Sequencing: Overcoming GC Bias through Trial and Error.
Lee H; Lee B; Kim DG; Cho YA; Kim JS; Suh YL
Cancer Res Treat; 2022 Jan; 54(1):75-83. PubMed ID: 33940787
[TBL] [Abstract][Full Text] [Related]
7. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
[TBL] [Abstract][Full Text] [Related]
8. Multigene profiling to identify alternative treatment options for glioblastoma: a pilot study.
Tabone T; Abuhusain HJ; Nowak AK; ; Erber WN; McDonald KL
J Clin Pathol; 2014 Jul; 67(7):550-5. PubMed ID: 24695838
[TBL] [Abstract][Full Text] [Related]
9. TERT promoter mutations in primary and secondary glioblastomas.
Nonoguchi N; Ohta T; Oh JE; Kim YH; Kleihues P; Ohgaki H
Acta Neuropathol; 2013 Dec; 126(6):931-7. PubMed ID: 23955565
[TBL] [Abstract][Full Text] [Related]
10. Deep sequencing of multiple regions of glial tumors reveals spatial heterogeneity for mutations in clinically relevant genes.
Kumar A; Boyle EA; Tokita M; Mikheev AM; Sanger MC; Girard E; Silber JR; Gonzalez-Cuyar LF; Hiatt JB; Adey A; Lee C; Kitzman JO; Born DE; Silbergeld DL; Olson JM; Rostomily RC; Shendure J
Genome Biol; 2014 Dec; 15(12):530. PubMed ID: 25608559
[TBL] [Abstract][Full Text] [Related]
11. Using genomics to guide treatment for glioblastoma.
Young JS; Prados MD; Butowski N
Pharmacogenomics; 2018 Oct; 19(15):1217-1229. PubMed ID: 30203716
[TBL] [Abstract][Full Text] [Related]
12. Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies.
Xiu J; Piccioni D; Juarez T; Pingle SC; Hu J; Rudnick J; Fink K; Spetzler DB; Maney T; Ghazalpour A; Bender R; Gatalica Z; Reddy S; Sanai N; Idbaih A; Glantz M; Kesari S
Oncotarget; 2016 Apr; 7(16):21556-69. PubMed ID: 26933808
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients.
Felsberg J; Rapp M; Loeser S; Fimmers R; Stummer W; Goeppert M; Steiger HJ; Friedensdorf B; Reifenberger G; Sabel MC
Clin Cancer Res; 2009 Nov; 15(21):6683-93. PubMed ID: 19861461
[TBL] [Abstract][Full Text] [Related]
14. New prognostic factor telomerase reverse transcriptase promotor mutation presents without MR imaging biomarkers in primary glioblastoma.
Ersoy TF; Keil VC; Hadizadeh DR; Gielen GH; Fimmers R; Waha A; Heidenreich B; Kumar R; Schild HH; Simon M
Neuroradiology; 2017 Dec; 59(12):1223-1231. PubMed ID: 28894890
[TBL] [Abstract][Full Text] [Related]
15. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
16. Imaging genomics of Glioblastoma: state of the art bridge between genomics and neuroradiology.
ElBanan MG; Amer AM; Zinn PO; Colen RR
Neuroimaging Clin N Am; 2015 Feb; 25(1):141-53. PubMed ID: 25476518
[TBL] [Abstract][Full Text] [Related]
17. Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in
Felsberg J; Hentschel B; Kaulich K; Gramatzki D; Zacher A; Malzkorn B; Kamp M; Sabel M; Simon M; Westphal M; Schackert G; Tonn JC; Pietsch T; von Deimling A; Loeffler M; Reifenberger G; Weller M;
Clin Cancer Res; 2017 Nov; 23(22):6846-6855. PubMed ID: 28855349
[No Abstract] [Full Text] [Related]
18. Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers.
Korshunov A; Ryzhova M; Hovestadt V; Bender S; Sturm D; Capper D; Meyer J; Schrimpf D; Kool M; Northcott PA; Zheludkova O; Milde T; Witt O; Kulozik AE; Reifenberger G; Jabado N; Perry A; Lichter P; von Deimling A; Pfister SM; Jones DT
Acta Neuropathol; 2015 May; 129(5):669-78. PubMed ID: 25752754
[TBL] [Abstract][Full Text] [Related]
19. Practical Bioinformatic DNA-Sequencing Pipeline for Detecting Oncogene Amplification and EGFRvIII Mutational Status in Clinical Glioblastoma Samples.
Miller ML; Tome-Garcia J; Waluszko A; Sidorenko T; Kumar C; Ye F; Tsankova NM
J Mol Diagn; 2019 May; 21(3):514-524. PubMed ID: 31000415
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics.
Li R; Chen X; You Y; Wang X; Liu Y; Hu Q; Yan W
Oncotarget; 2015 Oct; 6(31):30968-74. PubMed ID: 26427041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
